Introduction
============

Lung cancer is the most common malignancy and the leading cause of cancer-associated mortality worldwide, primarily in the form of squamous cell carcinoma ([@b1-mmr-16-01-0746],[@b2-mmr-16-01-0746]). Many cases are diagnosed at an advanced stage, which may be responsible for the poor prognosis in lung cancer patients. Thus, determining novel and effective therapeutic targets is indispensable for lung squamous cell carcinoma (LSCC) treatment, and may provide novel insights into carcinogenesis.

Carcinogenesis is a multistep progress. Tumor-suppressor genes or oncogenes serve critical roles in regulating tumor-associated biological process, including proliferation, apoptosis, migration and invasion ([@b3-mmr-16-01-0746]--[@b5-mmr-16-01-0746]). Previous studies have identified many classic tumor suppressor genes, including reversion-inducing-cysteine-rich protein with kazal motifs (*RECK*), breast cancer 1 (*BRCA1*) and Ras association domain family 1 isoform A (*RASSF1A*) ([@b6-mmr-16-01-0746]--[@b8-mmr-16-01-0746]). These genes were hypermethylated in various types of tumors and were involved in tumor-associated biological processes. For example, promoter methylation of *RECK* contributes to metastasis of osteosarcoma ([@b9-mmr-16-01-0746]). *BRCA1* negatively mediates cell proliferation, and its mRNA levels were downregulated by methylation ([@b10-mmr-16-01-0746]). The epigenetically inactivated *RASSF1A* gene was associated with poor prognosis and advanced tumor stage ([@b11-mmr-16-01-0746]). Therefore, revealing the potential underlying mechanism and function of deregulated tumor-associated genes may have great benefit for the understanding of carcinogenesis. Protein tyrosine phosphatase receptor-type O (PTPRO) is a candidate tumor suppressor belonging to the protein tyrosine phosphatase (PTP) family, and is highly conserved in different species ([@b12-mmr-16-01-0746]). Previous studies have reported that DNA methylation is involved in the regulation of *PTPRO* in hepatocellular carcinomas ([@b13-mmr-16-01-0746]), lung cancer ([@b14-mmr-16-01-0746]), chronic lymphocytic leukemia ([@b15-mmr-16-01-0746]), esophageal squamous cell carcinoma ([@b16-mmr-16-01-0746]) and colorectal cancer ([@b17-mmr-16-01-0746]). Overexpression of PTPRO inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma and lymphoma ([@b18-mmr-16-01-0746],[@b19-mmr-16-01-0746]), while downregulation of *PTPRO* is associated with metastases in breast cancer ([@b20-mmr-16-01-0746]). *PTPRO* regulates mammary epithelial transformation via directly targeting the receptor tyrosine kinase ErbB2/human epidermal growth factor receptor 2 ([@b21-mmr-16-01-0746]). Although these studies suggested the candidate tumor suppressor role of *PTPRO*, the expression and biological function of *PTPRO* in LSCC remains to be fully elucidated.

The present study assessed the methylation and expression of *PTPRO* in LSCC cells and tissues, and the effect of overexpression of *PTPRO* on tumor growth. The CpG island of *PTPRO* exon 1 was hypermethylated in H520 and SK-MES-1 cells. In LSCC patients, the significantly higher methylation levels of *PPTPRO* was correlated with its decreased mRNA levels. Furthermore, upregulation of *PTPRO* significantly inhibited cell proliferation and colony formation *in vitro*, and the tumorigenicity of H520 cells *in vivo*. These data suggested that epigenetic regulation of *PTPRO* expression is likely to be involved in the progression of LSCC.

Materials and methods
=====================

### Tissue samples

Primary tumors and corresponding adjacent healthy tissues were obtained from 65 patients, including 40 men and 25 women, with a mean age 61.7 years, who were diagnosed in Department of Thoracic Surgery, Hubei Cancer Hospital (Wuhan, China) between March 2010 and July 2011. All the tumors used in this study were squamous cell carcinoma, and tumor stages were confirmed by pathologists according to the criterion of Union for International Cancer Control. The clinical characteristics were obtained from medical records. This study was approved by the ethical committees of Hubei Cancer Hospital and written informed consent was obtained prior to surgery. All tissue specimens were surgically resected and immediately flash-frozen in liquid nitrogen, and stored at −80°C.

### Cell lines and cDNA transfection

The H520 and SK-MES-1 LSCC cell lines and the BEAS-2B healthy human bronchial epithelial cell line were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in the conditions as recommended ([@b22-mmr-16-01-0746]). The cells were maintained in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum and 100 U/ml penicillin sodium at 37°C in an humidified atmosphere of 5% CO~2~. To construct a vector stably expressing *PTPRO*, a pcDNA 3.1-Hemagglutinin A (HA)-tagged vector (Invitrogen; Thermo Fisher Scientific, Inc.) was purchased and used in this study. The cDNA encoding the complete coding region of human *PTPRO* cDNA was obtained from GeneBank (NM_030667.2). The HA label was introduced to protein C in the vector, and the *E.coli* strain of DH5a was also preserved in a laboratory at Hubei Cancer Hospital. A pcDNA-PTPRO-HA expression vector was established using a traditional method ([@b23-mmr-16-01-0746]).

### DNA extraction and methylation analysis

Total amounts of DNA (2 µg) were extracted from cells and tissues using a DNeasy Blood & Tissue kit (Qiagen GmbH, Germany) according to manufacturer\'s protocol. The quantity of DNA was tested by a NanoDrop spectrophotometer (Thermo Fisher Scientific, Inc.), and stored at −80°C until use. All DNA samples were treated using an EpiTect Bisulfite kit (Qiagen GmbH), and converted-DNA was used as a template in next step analysis. For bisulfite sequencing-polymerase chain reaction (BSP-PCR) analysis, the PCR reaction was conducted in 50 µl solution containing converted-DNA (200 ng), dNTP (200 nM for each), forward and reverse primers (50 pM), and *Taq* DNA Polymerase (2.5 U; Thermo Fisher Scientific, Inc.). The 4 µl PCR products (0.1 µg/µl) were ligated into the PMD18T vector. Recombinant vectors were then transformed to *E. coli* and the positive colonies were selected for sequencing. As inactivation of tumor suppressor genes may occur via hypermethylation of CpG islands upstream of the transcription start site, the present study selected a target region spanning from −405 to −74 (containing 23 CpG sites) in the BSP analysis, and the primers for PTPRO (forward: 5′-GAGGTTGTTGTTATTTTATGGG-3′; reverse: 5′-TAAAACTACAACCTCAAACCCT-3′) were used. Methylation specific PCR (MSP) assays were performed using a Techne-512 system (Techne, Staffordshire, UK) and included an initial incubation at 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 30 sec, annealing at 56°C for 20 sec, extension at 72°C for 20 sec and a final extension step at 72°C for 10 min. One pair of primers for methylated PTPRO (forward: 5′-TGTTGTTAGAGGATTACGGC-3′; reverse: 5′-CAAAAACGTACCAAACGCTA-3′) and unmethylated PTPRO (forward: 5′-TTTTGTTGTTAGAGGATTATGGT-3′; reverse: 5′-TCCAAAAACATACCAAACACTAC-3′) were used to amplify methylation and unmethylation alleles of PTPRO, respectively. Quantitative (Q) MSP was performed to detect the methylation levels of *PTPRO* in tumors and matched healthy tissue, and the quantity of methylated *PTPRO* was normalized to β-actin. Briefly, 10 ng bisulfite-coverted DNA was used in the QMSP assay in 384-well plates with a LightCycler480 system (Roche Diagnostics, Basel, Switzerland). The PCR reaction included an initial incubation at 95°C for 5 min, followed by 45 cycles of denaturation at 95°C for 30 sec, 58°C for 10 sec, 72°C for 20 sec and 80°C for 1 sec. Each plate consisted of clinical samples, water blanks and a positive control. Serial dilutions of the H520 *PTPRO* methylation-positive cell line were used for constructing the calibration curve. QMSP analyses yield values are expressed as ratios between two absolute measurements (*PTPRO*:β-actin ×100) ([@b24-mmr-16-01-0746]). Each sample was analyzed in duplicate.

### 5-Aza-2′-deoxycytidine (5-AZA) treatment

For the demethylation assay, 1×10^5^ H520 and SK-MES-1 cells were seeded into 6-well plates, cultured for 24 h and treated with 0, 2.5 or 5 µM 5-AZA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). Fresh medium containing 5-AZA was changed every 24 h for 3 days and the treated cells were harvested for reverse transcription-quantitative (RT-q) PCR analysis.

### RNA extraction and RT-qPCR analysis

Total RNA was isolated from cells using TRIzol^®^ regent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. Total RNA was reverse transcribed into cDNA, and this procedure was performed once using the PrimeScript RT reagent kit (Takara Bio, Inc., Otsu, Japan), which was subsequently used for RT-qPCR analysis using an ABI 7500 fast Sequence Detector (ABI, Carlsbad, CA, USA). The reaction conditions were as follows: an initial predenaturation step at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 10 sec, annealing at 60°C for 20 sec and extension at 72°C for 30 sec. β-actin served as the endogenous control for detection of mRNA expression levels ([@b25-mmr-16-01-0746]). Relative quantification analysis was performed using the 2^−ΔΔCq^ method ([@b25-mmr-16-01-0746]). The following primers for *PTPRO* (NM_030667.2, transcript variant 1) were used: Forward, 5′-ACTGCCCCTTATCCACCTCA-3′ and reverse, 5′-TGTTGCCCGAGGGAATTTCA-3′.

### Cell proliferation and colony formation assays

Cell proliferation was assessed by MTT assay. H520 and SK-MES-1 cells were seeded into 96-well culture plates at a density of 1.5×10^3^ per well. after 1--6 days, cells were incubated with 20 µl MTT (5 mg/ml, Sigma-Aldrich; Merck KGaA) for 4 h at 37°C. The cell medium was removed and 150 µl dimethyl sulfoxide was added to each well. The absorbance was measured at a wavelength of 490 nm using a microtiter plate reader (Tecan Schweiz AG, Männedorf, Switzerland). To investigate clonogenic ability, cells were transfected with *PTRPO* or an empty vector, and subsequently seeded into 6-well (200 cells per well) plates. The culture medium was replaced every 3 days. After 2 weeks, the medium was removed and the plates were washed twice using PBS. The colonies were fixed in methanol at −20°C for 5 min, stained with 0.1% crystal violet (Sigma-Aldrich; Merck KGaA), and counted using an inverted microscope (Nikon Corporation, Tokyo, Japan) in five random fields.

### Tumorigenicity analysis

Xenograft experiments were performed to evaluate the tumorigenicity of H520 cells transfected with *PTPRO* or an empty vector. Briefly, 1×10^7^ H520 cells resuspended in 200 µl PBS were subcutaneously injected into the flanks of athymic nude male mice (n=5; age, 4 weeks), which were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Animal experiments were conducted in accordance with guidelines approved by the Institutional Animal Care and Use Committee of Hubei Cancer Hospital. The mice were maintained at a temperature of 18--22°C and humidity of 50--60% under 12:12 h light-dark cycle with had free access food and water. Each mouse was injected in left flank with the *PTPRO* vector, and in the right flank with the empty vector. A total of 28 days after injection, tumors were harvested, weighed and assayed for mRNA expression.

### Western blot analysis

Equal amount of protein extracts were lysed using radioimmunoprecipitation assay lysis buffer (Sigma-Aldrich; Merck KGaA). Cells were centrifuged in a microcentrifuge at 12,000 × g for 15 min at 4°C to collect the supernatant. Protein concentration was determined using a Bicinchoninic Acid Protein Assay kit (Pierce; Thermo Fisher Scientific, Inc.). A total of 30 µg protein were separated by 10% SDS-PAGE and then transferred onto polyvinyl fluoride membranes (Merck KGaA). The membranes were blocked with 5% fat-free milk in Tris-buffered saline for 1 h, and incubated with anti-PTPRO (1:1,000; catalog no. sc-365354; Santa Cruz Biotechnology, Dallas, TX, USA) and anti-β-actin (1:2,000; catalog no. 4970, Cell Signaling Technology, Inc., Danvers, MA, USA) primary antibodies at 4°C overnight. The membranes were washed three times with Tris-buffered saline containing 0.1% Tween and incubated for 2 h at room temperature with a horseradish peroxidase-conjugated goat anti-rabbit (catalog no. 7074; 1:1000; Cell Signaling Technology, Inc.) or anti-mouse secondary antibody (catalog no. sc-516102, 1:2000, Santa Cruz Biotechnology). Proteins were visualized using a Bio-Rad ChemiDoc Imaging system (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

### Statistical analysis

Statistical analysis was performed using Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA). Data are expressed as the mean ± standard error of three independent experiments. Two-way ANOVA followed by Bonferroni correction was used to determine the statistical significance when the number of groups was more than three. The methylation and expression levels of *PTPRO* in tumors and healthy controls were compared using paired-samples t-test. The overall survival of LSCC patients were analyzed using the Log-rank test. All tests were two sided and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### CpG island of PTPRO exon 1 is hypermethylated in LSCC cells and tissues

As the methylation status of *PTPRO* in LSCC cells is unclear, a BSP assay was performed in H520 and SK-MES-1 cells, and BEAS-2B cells served as a healthy control. As presented in [Fig. 1A and B](#f1-mmr-16-01-0746){ref-type="fig"}, the CpG island in the 1st exon was hypermethylated in H520 and SK-MES-1 cells, while partially methylated in BEAS-2B cells. Following this, the methylation status of *PTPRO* in LSCC tissues was assessed using the MSP method. The intensity of methylated alleles was noticeably increased compared with unmethylated alleles ([Fig. 1C](#f1-mmr-16-01-0746){ref-type="fig"}). To assess if a demethylation agent could restore transcriptional activity, LSCC cells were treated with 0, 2.5 or 5 µM 5-AZA for 72 h. The mRNA expression levels of *PTPRO* were significantly increased following 5-AZA treatment in all groups except the 2.5 µM treatment group in SK-MES-1 cells ([Fig. 1D](#f1-mmr-16-01-0746){ref-type="fig"}). These data demonstrated that the CpG island of *PTPRO* exon 1 was hypermethylated in LSCC cells and tissues, suggesting that the epigenetic regulation of *PTPRO* may serve a role in LSCC tumorigenesis.

### PTPRO is epigenetically downregulated in LSCC tissues

To understand the methylation and mRNA levels of *PTPRO*, QMSP and RT-qPCR analyses were performed in LSCC and matched healthy tissues. The methylation levels of *PTPRO* were significantly increased in LSCC tissues compared with healthy controls (0.0438±0.0263 vs. 0.0381±0.0264; P=0.0005; [Fig. 2A](#f2-mmr-16-01-0746){ref-type="fig"}). The mean methylation level of *PTPRO* in tumors was used as cut-off to divide cases into two groups (high- or low-methylation). A low level of *PTPRO* methylation was significantly associated with high overall survival probability in LSCC patients (P=0.027; [Fig. 2B](#f2-mmr-16-01-0746){ref-type="fig"}). Furthermore, the mRNA expression levels of *PTPRO* were markedly reduced in tumors compared with healthy tissues (66.87±12.11 vs. 68.24±11.81; P=0.005; [Fig. 2C](#f2-mmr-16-01-0746){ref-type="fig"}), and low expression of *PTPRO* (\<the mean of mRNA levels of *PTPRO* in tumors) was associated with poor prognosis of patients (P=0.002; [Fig. 2D](#f2-mmr-16-01-0746){ref-type="fig"}). Pearson correlation coefficient analysis identified an inverse correlation between methylation and mRNA levels of *PTPRO* in tumors (Pearson r=−0.409; P=0.0007; [Fig. 2E](#f2-mmr-16-01-0746){ref-type="fig"}).

Subsequently, the present study verified whether the methylation or expression of *PTPRO* was associated with clinicopathological features of patients. As presented [Table I](#tI-mmr-16-01-0746){ref-type="table"}, mRNA expression levels of *PTPRO* were significantly reduced in advanced tumors compared with early-stage tumors (P=0.042). The methylation or mRNA levels of *PTPRO* were not associated with other clinical parameters ([Table I](#tI-mmr-16-01-0746){ref-type="table"}). Univariate analysis demonstrated that the high methylation of *PTPRO*, low *PTPRO* mRNA, smoking, advanced tumor stage, higher T stage and lymph node metastasis were predictors of poor prognosis for patients, whereas only mRNA expression levels of *PTPRO* (P=0.005) and higher TNM stage (P=0.001) were identified as significantly independent prognostic factors in multivariate analysis, with relative risks of 2.826 and 3.714, respectively ([Table II](#tII-mmr-16-01-0746){ref-type="table"}). Taken together, these data suggested that epigenetically downregulated PTPRO may be involved in LSCC development and may be a potential prognostic marker. Detailed clinical and molecular data of the patients are presented in [Table III](#tIII-mmr-16-01-0746){ref-type="table"}.

### PTPRO inhibits cell viability in vitro

The expression levels of *PTPRO* in transfected cells and control cells were detected. The mRNA ([Fig. 3A](#f3-mmr-16-01-0746){ref-type="fig"}) and protein ([Fig. 3B](#f3-mmr-16-01-0746){ref-type="fig"}) expression levels of *PTPRO* were upregulated in H520 and SK-MES-1 cells transfected with stably expressing *PTPRO* vectors in comparison with control cells and non-transfected cells. The results of MTT demonstrated that when compared with the empty vector group (control) and non-transfected group (untreated), the proliferation of LSCC cells was significantly inhibited in overexpressing *PTPRO* cells ([Fig. 3C](#f3-mmr-16-01-0746){ref-type="fig"}). Colony formation assay was performed to evaluate the effect of *PTPRO* on LSCC cells. As a result, the number of colonies were significantly reduced in H520 and SK-MES-1 cells transfected with *PTPRO* expressing vectors, compared with control and untreated cells ([Fig. 3D](#f3-mmr-16-01-0746){ref-type="fig"}). These *in vitro* analyses demonstrated the inhibitory effect of *PTPRO* on cell viability.

### PTPRO impairs the tumorigenicity of H520 cells in vivo

The inhibitory role of *PTPRO* was further confirmed using a xenograft model of H520 cells in nude mice. As expected, there was a significant reduction in tumor volume and weight in the *PTPRO* overexpression group compared with the empty vector group ([Fig. 4A and B](#f4-mmr-16-01-0746){ref-type="fig"}). In addition, mRNA expression levels of *PTPRO* were upregulated in tumors injected with *PTPRO* vectors ([Fig. 4C](#f4-mmr-16-01-0746){ref-type="fig"}).

Discussion
==========

Many LSCC patients are already in the advanced stages when diagnosed, rendering treatment difficult. The initiation and progression of squamous cell carcinoma is a complex process involving the abnormalities of a variety of oncogenes and tumor suppressors ([@b26-mmr-16-01-0746],[@b27-mmr-16-01-0746]). The present study focused on the novel tumor suppressor *PTPRO*.

It is well known that the cell tyrosine phosphorylation levels are co-regulated by PTP and protein tyrosine kinase (PTK); dysfunction of tyrosine phosphatase is closely associated with the occurrence of a variety of human tumors ([@b28-mmr-16-01-0746]). Previous studies have demonstrated that overexpression of PTP in cancer cells may reverse the malignant transformation induced by PTK ([@b29-mmr-16-01-0746]). *PTPRO* is a member of the PTP family that has been reported to be frequently methylated, and is characterized as a tumor suppressor gene in the occurrence and development of many malignancies ([@b13-mmr-16-01-0746]--[@b16-mmr-16-01-0746]). The present study examined H520 and SK-MES-1 LSCC cells and LSCC cases for analysis. The CpG island of *PTPRO* exon1 was revealed to be hypermethylated, which was consistent with previous studies ([@b14-mmr-16-01-0746]). Additionally, in the present study, high methylation or low expression of *PTPRO* were associated with poor prognosis. Similar results have been reported in breast ([@b21-mmr-16-01-0746],[@b30-mmr-16-01-0746]) and colorectal ([@b31-mmr-16-01-0746]) cancer. Li *et al* ([@b30-mmr-16-01-0746]) reported that methylation of *PTPRO* was an independent predictor for survival. However, mRNA expression of *PTPTO*, rather than methylation, was an independent factor in the present study. All these data strongly suggested that *PTPRO* is involved in tumorigenesis and may serve as a valuable prognostic marker in cancers.

Although the function and underlying mechanism of *PTPRO* has been documented in former studies ([@b18-mmr-16-01-0746]--[@b20-mmr-16-01-0746]), the biological effect of *PTPRO* in LSCC remains unclear. The present study demonstrated that ectopic *PTPRO* expression significantly inhibited the proliferation rate and colony formation ability of cells. Previous investigations observed a similar effect in lung adenocarcinoma and lymphoma ([@b14-mmr-16-01-0746],[@b19-mmr-16-01-0746]). *PTPRO* was also reported to be involved in other critical biological processes including angiogenesis, metastasis and apoptosis ([@b18-mmr-16-01-0746],[@b20-mmr-16-01-0746],[@b21-mmr-16-01-0746]). Therefore, *PTPRO* may serve as a multi-functional regulator in tumorigenesis. In the present study, tumorigenicity analysis confirmed the tumor suppressive effect of *PTPRO in vivo*. Taken together, these findings expanded current knowledge of *PTPRO* in LSCC, suggesting the potential value of *PTPRO* as a therapeutic target.

In conclusion, the present study demonstrated that *PTPRO* inhibits tumor growth *in vitro* and *in vivo*, indicating the tumor suppressive function of *PTPRO* in LSCC. This study highlights PTPRO as an epigenetically silenced gene, and a candidate tumor-suppressor of LSCC.

![CpG island of the PTPRO promoter (from −405 to −74) is hypermethylated in LSCC cells. (A) Dot graph of BSP data in H520 and SK-MES-1 LSCC cells and BEAS-2B healthy control cells. The BSP-tested region contained 23 CpG sites. Black dot, methylated; white dot, unmethylated; stub, not available. (B) Representative sequences of BSP in H520 and BEAS-2B cells. (C) Methylation-specific polymerase chain reaction of PTPRO in five LSCC tissues. M, methylation alleles; U, unmethylation alleles. (D) Reverse transcription-quantitative polymerase chain reaction analysis of PTPRO mRNA expression levels after 0, 2.5 or 5 µM 5-AZA treatment for 72 h. Data are presented as the mean ± standard deviation. \*P\<0.05; \*\*P\<0.01; \*\*\*P\<0.001. ns, non-significant; 5AZA, 5-Aza-2′-deoxycytidine; BSP, bisulfite sequencing; LSCC, lung squamous cell carcinoma, PTPRO, protein tyrosine phosphatase receptor-type O.](MMR-16-01-0746-g00){#f1-mmr-16-01-0746}

![Methylation and expression levels of PTPRO in 65 LSCC tissues and adjacent healthy tissues. (A) Quantitative methylation-specific polymerase chain reaction analysis of PTPRO demonstrated that the methylation level of PTPRO was significantly increased in tumors. (B) Higher PTPRO methylation levels in patients predicted poor prognosis. (C) The mRNA expression levels of PTPRO were detected in tumors or matched healthy tissue by reverse transcription-quantitative polymerase chain reaction. (D) Overall survival analysis indicated that reduced PTPRO mRNA expression levels in patients was associated with poor prognosis. (E) Expression of PTPRO was inversely correlated with its methylation in tumors. Data are presented as the mean ± standard deviation. HT, healthy tissues; LSCC, lung squamous cell carcinoma, PTPRO, protein tyrosine phosphatase receptor-type O.](MMR-16-01-0746-g01){#f2-mmr-16-01-0746}

![Overexpression of PTPRO inhibits LSCC cell growth *in vitro*. (A) The mRNA expression levels of PTPRO were markedly increased following transfection with a pcDNA-PTPRO vector. (B) The protein expression levels of PTPRO were detected by western blotting. (C) The effect of PTPRO on cell proliferation was measured by MTT assay. (D) Representative micrographs and quantification of stained H520 and SK-MES-1 cell colonies. Data are presented as the mean ± standard deviation. \*P\<0.05; \*\*P\<0.01. LSCC, lung squamous cell carcinoma, PTPRO, protein tyrosine phosphatase receptor-type O; OD, optical density; U, untreated; C, control; P, PTPRO..](MMR-16-01-0746-g02){#f3-mmr-16-01-0746}

![PTPRO inhibits tumor growth *in vivo*. (A) pcDNA-PTPRO- and control vector- transfected H520 cells were injected subcutaneously into the flanks of nude mice. Tumor volumes were measured every 7 days. Tumor volumes was significantly reduced in tumors stably expressing PTPRO. (B) Tumor weight was calculated at 4 weeks post injection. (C) mRNA expression levels of PTPRO in xenograft tumors were confirmed by reverse transcription-quantitative polymerase chain reaction. Data are presented as the mean ± standard deviation. \*\*P\<0.01. PTPRO, protein tyrosine phosphatase receptor-type O.](MMR-16-01-0746-g03){#f4-mmr-16-01-0746}

###### 

Associations between clinicopathological features and methylation or mRNA expression levels of PTPRO in lung squamous cell carcinoma.

  Variable          Total (n=65)   PTPRO Methylation   P-value   PTPRO mRNA    P-value
  ----------------- -------------- ------------------- --------- ------------- ---------
  Gender                                               0.322                   0.249
    Female          25             0.0471±0.0254                 64.69±12.13   
    Male            40             0.0417±0.0269                 68.23±12.04   
  Age (years)                                          0.126                   0.133
    \<60            28             0.0389±0.0264                 69.11±13.26   
    ≥60             37             0.0475±0.0259                 65.17±11.04   
  Smoking                                              0.896                   0.788
    Never           31             0.0411±0.0201                 67.33±12.51   
    Past, current   34             0.0462±0.0309                 66.44±11.90   
  TNM stage                                            0.237                   0.042
    I, II           34             0.0396±0.0233                 70.55±12.49   
    III, IV         31             0.0484±0.0289                 62.82±10.42   
  pT stage                                             0.703                   0.603
    T1-2            43             0.0429±0.0261                 67.56±13.13   
    T3-4            22             0.0455±0.0271                 65.51±9.955   
  pN stage                                             0.263                   0.286
    N0              17             0.0374±0.0222                 70.64±3.001   
    N1-3            48             0.0461±0.0274                 65.53±1.711   

Never, no smoking history; Past, stopped smoking for \<1 year; current, current smoker; SD, standard deviation; TNM, tumor node metastasis; PTPRO, protein tyrosine phosphatase receptor-type O.

###### 

Clinical characteristics of lung squamous cell carcinoma patients correlates with overall survival.

                                  Univariate analysis   Multivariate analysis                                  
  ------------------------------- --------------------- ----------------------- ------- ------- -------------- -------
  PTPRO methylation (low/high)    2.108                 1.068--4.163            0.032                          
  PTPRO mRNA (high/low)           2.971                 1.442--6.121            0.003   2.826   1.364--5.853   0.005
  Gender (female/male)            1.15                  0.569--2.326            0.696                          
  Age (\<60 y/≥60 y)              1.037                 0.991--1.085            0.119                          
  Smoking (never/past, current)   2.113                 1.042--4.286            0.038                          
  TNM stage (I, II/III, IV)       4.145                 1.998--8.061            0.000   3.714   1.771--7.792   0.001
  T stage (T1-2/T3-4)             2.288                 1.149--4.555            0.018                          
  N stage (N0/N1-3)               2.743                 1.060--7.101            0.038                          

HR, hazard ratio; CI, confidence interval; TNM, tumor node metastasis; PTPRO, protein tyrosine phosphatase receptor-type O.

###### 

Detailed clinical and molecular data of cases.

  IID   Methy (H)   Methy (T)   mRNA (H)   mRNA (T)   Gender   Age   Smoking   TNM      Survival   Months
  ----- ----------- ----------- ---------- ---------- -------- ----- --------- -------- ---------- --------
    1   0.0416      0.0445      78.02      73.09      M        57    current   T3N2M0   No         16
    2   0.0253      0.0384      71.13      71.283     M        66    current   T1N2M0   No         32
    3   0.0553      0.0623      56.214     57.89      M        45    past      T3N0M0   No         52
    4   0.0363      0.0487      67.083     64.097     F        61    never     T2N0M0   Yes        52
    5   0.00652     0.0149      79.032     78.37      M        55    current   T1N1M0   Yes        50
    6   0.0272      0.0368      57.734     51.98      M        59    never     T2N1M0   No         50
    7   0.0966      0.1252      76.04      72.01      M        58    current   T1N2M0   Yes        54
    8   0.0357      0.0427      74.32      72.094     M        72    never     T3N0M0   Yes        41
    9   0.0623      0.0619      52.77      60.67      F        64    never     T3N0M0   Yes        41
  10    0.0422      0.0534      74.04      70.32      M        62    never     T2N1M0   Yes        43
  11    0.0342      0.0415      68.32      74.89      M        59    never     T2N1M0   No         44
  12    0.0164      0.0268      96.43      92.384     M        60    current   T1N1M0   Yes        51
  13    0.1026      0.1154      69.05      66.391     M        66    current   T4N1M0   No         19
  14    0.0949      0.1045      60.21      63.42      F        68    current   T1N1M0   No         42
  15    0.0713      0.0643      70.14      70.06      M        72    past      T2N2M0   No         34
  16    0.0532      0.0503      60.69      64.382     M        68    current   T3N2M0   No         13
  17    0.0106      0.0483      66.985     66.45      F        55    never     T2N2M0   Yes        52
  18    0.0214      0.0312      84.376     89.103     F        53    never     T1N0M0   Yes        47
  19    0.0123      0.0164      62.165     70.01      F        62    never     T2N2M0   Yes        57
  20    0.0226      0.0324      58.54      53.75      M        64    current   T1N1M0   No         12
  21    0.0351      0.0456      81.23      75.376     F        59    never     T2N1M0   Yes        49
  22    0.0556      0.0575      44.01      50.09      F        77    never     T3N1M1   No         16
  23    0.0434      0.0537      62.93      61.067     M        62    past      T1N2M0   No         24
  24    0.0153      0.0292      72.71      67.651     M        69    never     T3N1M0   Yes        49
  25    0.0441      0.0439      59.92      51.06      M        68    current   T3N1M0   No         25
  26    0.0532      0.0528      54.04      52.39      F        72    never     T2N0M0   Yes          9
  27    0.0503      0.0645      60.87      57.09      F        75    never     T1N1M0   No         48
  28    0.0413      0.0392      58.36      55.09      F        55    never     T1N0M0   Yes        46
  29    0.0096      0.0126      74.09      73.213     M        67    current   T2N0M0   Yes        47
  30    0.0634      0.0714      73.98      69.08      M        63    past      T2N1M0   No         46
  31    0.00921     0.0105      85.362     82.99      M        62    current   T2N1M0   Yes        42
  32    0.04632     0.0443      50.093     42.78      F        63    never     T1N2M0   No         27
  33    0.02752     0.03648     59.986     57.853     M        67    current   T3N2M0   Yes        39
  34    0.0264      0.0336      70.84      67.895     F        77    never     T1N1M0   Yes        52
  35    0.0144      0.0293      63.468     60.432     M        57    past      T2N2M0   Yes        49
  36    0.01123     0.01293     64.35      65.783     M        65    current   T2N3M0   No           9
  37    0.0261      0.0359      67.94      71.67      M        53    current   T1N0M0   No         40
  38    0.0292      0.0366      68.17      65.332     F        73    never     T3N1M0   No         35
  39    0.0061      0.0077      81.653     80.56      M        58    past      T2N0M0   Yes        48
  40    0.04493     0.0523      60.41      58.24      F        70    never     T3N1M1   No           3
  41    0.0236      0.0413      68.56      64.02      F        52    never     T2N1M0   Yes        46
  42    0.0958      0.0914      59.054     55.67      F        64    current   T1N2M0   No         14
  43    0.0142      0.0317      71.23      68.541     M        66    current   T2N2M0   No         22
  44    0.01116     0.01157     90.01      94.03      M        55    past      T1N0M0   Yes        58
  45    0.08357     0.01094     78.55      77.83      F        59    never     T3N1M0   Yes        48
  46    0.0607      0.0555      61.64      60.098     M        51    never     T3N1M0   No         32
  47    0.0578      0.0586      71.62      68.154     M        53    current   T1N1M0   Yes        31
  48    0.0545      0.0523      57.43      50.82      M        64    current   T1N1M0   Yes        43
  49    0.0945      0.1054      76.841     74.54      F        69    never     T3N2M0   Yes        10
  50    0.0582      0.0693      48.68      45.469     M        60    never     T3N2M0   No           9
  51    0.00843     0.01128     74.71      73.52      M        55    past      T3N1M0   Yes        45
  52    0.0446      0.0431      73.12      66.376     F        68    never     T1N0M0   No         35
  53    0.0882      0.0925      64.89      61.87      M        56    current   T2N0M0   Yes        46
  54    0.00948     0.01237     88.56      89.82      F        59    never     T1N1M0   Yes        46
  55    0.01512     0.02538     73.02      72.02      M        78    past      T3N2M0   No         18
  56    0.0197      0.0336      69.332     66.365     M        63    never     T3N0M0   No         27
  57    0.0703      0.0655      42.24      40.08      F        58    current   T1N2M0   No         31
  58    0.01692     0.02335     83.01      82.32      M        64    never     T1N0M0   Yes        52
  59    0.01808     0.04049     44.33      43.9       M        47    current   T2N1M1   No         6
  60    0.0156      0.01964     74.841     73.546     F        57    never     T3N2M0   Yes        37
  61    0.00938     0.01015     90.091     87.569     M        50    never     T2N1M0   Yes        53
  62    0.02085     0.02322     71.841     65.323     F        52    past      T3N0M0   No         28
  63    0.0203      0.02813     73.841     72.04      F        59    current   T2N2M0   No         20
  64    0.03256     0.0463      47.65      56.33      M        52    current   T2N3M0   No         27
  65    0.01014     0.01379     83.01      87.83      M        62    never     T3N0M0   Yes        49

Methy (H), methylation levels in healthy tissues; Methy (T), methylation levels in tumors; mRNA (H), mRNA levels in healthy tissues; mRNA (T), mRNA levels in tumors; F, female; M, male; Months, survival in months; TNM, tumor node metastasis.
